Business Wire

Blue Planet Science Fiction Film Festival Highlighted at the 77th Venice Film Festival

8.9.2020 15:33:00 EEST | Business Wire | Press release

Share

China’s Blue Planet Science-Fiction Film Festival was highlighted at the 77th Venice International Film Festival during the “Focus on China” side event earlier this week, bringing a glimpse of the future to the world’s oldest film festival.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200908005606/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Blue Planet Sci-Fi Film Festival presented at "Focus on China" event during Venice International Film Festival (Photo: Xinhuanet)

The Venice International Film Festival is one of the first major cultural events held in Europe since the outbreak of the COVID-19 pandemic. The fact that the festival - one of the film industry’s most important annual events - could go ahead offline as planned is a major boost to a sector that has been hit hard by the pandemic. The “Focus on China” event was held in the National Pavilion of Italy and streamed online.

2019 was an international breakthrough year for Chinese sci-fi cinema. November 2019 saw the inaugural Blue Planet Sci-Fi Film Festival, the first of its kind in China. It recorded great success, with 185 sci-fi films from 17 countries screened and a series of activities such as forums, masterclasses and exhibitions held.

The second Blue Planet Sci-Fi Film Festival will be held in November 2020. In light of the difficult times our world is going through, the theme of this year’s festival will be “empathy”. “Amidst this global crisis, it is more important than ever for people around the world to transcend barriers and engage with each other,” said the Blue Planet Organizing Committee in a message to the event.

Industry figures at the Venice Film Festival noted a buzz around the development of Chinese sci-fi. Roberto Stabile, head of international relations for the Italian motion picture association ANICA, said, “I was very impressed by this introduction to the Blue Planet Sci-Fi Film Festival, and look forward to welcoming our friends from the Blue Planet in Venice next year.”

Italian-Chinese filmmaker Shi Yangshi said, “Two years ago, Italian director Giuseppe Tornatore talked to me about Liu Cixin’s sci-fi novels and showed great interest in co-producing sci-fi films with China.” Italian producer Luca Confortini remarked, “China has a well-established film culture and its sci-fi films have been developing rapidly. The Blue Planet is an important and vibrant film event; I believe that China’s sci-fi film market will only grow bigger.”

Six Chinese-directed sci-fi short films chosen from the first Blue Planet were screened during the Film Festival.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Xinhuanet Europe
Wei Wang
info@xinhuaeurope.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye